Skip to main content
    P

    PTC Therapeutics Inc (PTCT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $60.99
    +1.32 (+2.21%)

    Market Cap: $4.98B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    38%(15/39)
    Avg Surprise
    +37.95%
    Streak
    2 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$0.30
    Range$0.24 - $0.36
    3 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$0.54-44.1%
    60d ago$0.31-3.2%
    30d ago$0.31-3.2%
    7d ago$0.38-21.1%
    Current$0.30
    Revenue Consensus
    $302M
    Range$274M - $322M
    12 analysts
    Period ending Dec 31, 2026
    EPS Consensus$1.32
    Range$1.03 - $1.62
    3 analysts
    Revenue Consensus
    $428M
    Range$364M - $475M
    13 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$1.32---
    Sep 26EST
    		-$0.30---
    Jun 26
    Reported Jul 30
    		$0.92$-0.17+641.18%Beat+210.8%
    Mar 26
    Reported May 7
    		$-0.03N/A+93.18%Beat-100.3%
    Dec 25
    Reported Feb 19
    		$-1.80$-0.40-350.00%Miss-426.9%
    Sep 25
    Reported Nov 4
    		$0.19N/A+117.12%Beat+114.0%
    Jun 25
    Reported Aug 7
    		$-0.83$-1.07+22.43%Beat+34.6%
    Mar 25
    Reported May 6
    		$10.04$-0.70+1534.29%Beat+936.7%
    Dec 24
    Reported Feb 27
    		$-0.34$-0.65+47.45%Beat-42.3%
    Sep 24
    Reported Nov 7
    		$-1.36$-1.66+18.07%Beat+22.3%
    Jun 24
    Reported Aug 8
    		$-1.27$-0.95-33.68%Miss+19.6%
    Mar 24
    Reported Apr 25
    		$-1.20$-1.10-9.09%Miss+36.2%
    Dec 23
    Reported Feb 29
    		$-0.24N/A-148.00%Miss+87.3%
    Sep 23
    Reported Oct 26
    		$-1.75$-1.55-12.90%Miss-14.4%
    Jun 23
    Reported Aug 3
    		$-1.58$-1.71+7.60%Beat+25.8%
    Mar 23
    Reported Apr 27
    		$-1.88$-1.63-15.34%Miss-5.6%
    Dec 22
    Reported Feb 21
    		$-1.89$-1.59-18.87%Miss+6.9%
    Sep 22
    Reported Oct 27
    		$-1.53$-1.26-21.43%Miss+19.0%
    Jun 22
    Reported Aug 4
    		$-2.13$-1.48-43.92%Miss-26.8%
    Mar 22
    Reported May 3
    		$-1.78$-1.66-7.23%Miss+2.7%
    Dec 21
    Reported Feb 22
    		$-2.03$-1.65-23.03%Miss-88.0%
    Sep 21
    Reported Oct 28
    		$-1.89$-1.89+0.00%Beat-83.5%
    Jun 21
    Reported Jul 29
    		$-1.68$-1.82+7.69%Beat+6.7%
    Mar 21
    Reported May 4
    		$-1.83$-1.62-12.96%Miss-1.1%
    Dec 20
    Reported Feb 25
    		$-1.08$-0.94-14.89%Miss+21.2%
    Sep 20
    Reported Oct 29
    		$-1.03$-0.45-128.89%Miss-15.7%
    Jun 20
    Reported Aug 5
    		$-1.80$-1.56-15.38%Miss-176.9%
    Mar 20
    Reported Apr 30
    		$-1.81$-1.33-36.09%Miss-98.9%
    Dec 19
    Reported Mar 2
    		$-1.37$-0.71-92.96%Miss-136.2%
    Sep 19
    Reported Oct 29
    		$-0.89$-0.88-1.14%Miss+16.0%
    Jun 19
    Reported Aug 6
    		$-0.65$-0.61-6.56%Miss-209.5%
    Mar 19
    Reported May 2
    		$-0.91$-0.68-33.82%Miss-97.8%
    Dec 18
    Reported Feb 28
    		$-0.58$-0.32-81.25%Miss-2033.3%
    Sep 18
    Reported Nov 5
    		$-1.06$-0.49-116.33%Miss-29.3%
    Jun 18
    Reported Aug 7
    		$-0.21N/A+52.27%Beat+52.3%
    Mar 18
    Reported May 9
    		$-0.46$-0.38-21.05%Miss+45.9%
    Dec 17
    Reported Mar 6
    		$0.03N/A+121.43%Beat+103.8%
    Sep 17
    Reported Nov 2
    		$-0.82$-0.67-22.39%Miss-
    Jun 17
    Reported Aug 8
    		$-0.44$-0.86+48.84%Beat-
    Mar 17
    Reported May 8
    		$-0.85$-0.93+8.60%Beat-
    Dec 16
    Reported Mar 16
    		$-0.78$-1.07+27.10%Beat-

    Key Metrics

    Valuation
    P/E Ratio-84.71EV/EBITDA29.62x
    Price/FCF-127.49xFCF Yield-0.78%
    Profitability
    Profit Margin-3.81%Operating Margin41.30%
    ROE-7740.00%ROIC18.05%
    Financial Health
    Debt/Equity-3.57xInterest CoverageN/A
    Current Ratio3.39xQuick Ratio3.28x
    Trading Statistics
    Beta0.49Avg Volume1.31M
    52-Week High$90.8752-Week Low$58.80

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$62.48
    SMA 20$63.42
    SMA 50$67.72
    SMA 200$71.49
    EMA 10$62.19
    EMA 20$63.60
    EMA 50$67.00
    EMA 200$69.34

    MACD

    Line: -1.90Signal: -1.78Hist: -0.12

    ADX

    ADX: 18.9+DI: 21.3-DI: 28.7

    Aroon & PSAR

    Aroon Up20.0
    Aroon Down96.0
    PSAR$65.33

    Bollinger Bands

    Upper Band$67.06
    Lower Band$59.79
    %B Position1147%(Upper)
    Band Width0.17

    RSI (14-Day)

    Neutral
    38.1

    Momentum Oscillators

    Stoch %K14.2
    Stoch %D21.0
    Williams %R-70.6
    ROC (10d)-4.9%
    Momentum-3.14
    CCI (20d)-129.1
    MFI (14d)39.5

    Volatility Measures

    ATR (14d)$2.19(3.6%)
    StdDev (20d)1.82
    Hist Vol40.2%(High)

    Volume Flow

    VWAP$61.06
    OBV59.3M
    AD Line12.1M
    CMF (20d)-0.169

    Volume Metrics

    Avg Vol (20d)1.3M
    Vol Ratio0.8x
    VWMA (20d)$63.65

    Pivot Points

    R3$62.53
    R2$61.61
    R1$60.64
    Pivot Point$59.72
    S1$58.75
    S2$57.83
    S3$56.86

    Advanced Oscillators

    TSI-24.78
    Ultimate Osc42.2
    KST-82.78

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$360.52M$272.55M$164.68M$211.01M$178.88M$1.18B$213.17M$196.79M$186.70M$210.12M$307.06M$196.58M
    Cost of Revenue$19.92M$28.03M$-24,282,000$0$11.42M$0$27.13M$0$15.53M$14.74M$-36,368,000$9.49M
    Gross Profit$340.60M$244.52M$188.96M$211.01M$167.46M$1.18B$186.04M$196.79M$171.18M$195.38M$343.42M$187.08M
    Operating Expenses$191.62M$199.56M$260.31M$207.99M$202.41M$205.87M$348.43M$251.30M$211.40M$240.83M$337.60M$305.25M
    R&D$99.15M$100.87M$133.13M$100.16M$112.99M$108.97M$124.77M$161.41M$132.17M$116.13M$121.35M$164.21M
    SG&A$80.63M$86.18M$96.87M$84.05M$85.26M$80.96M$84.68M$73.46M$69.50M$73.27M$76.29M$80.89M
    Operating Income$148.98M$44.96M$-71,349,000$3.02M$-34,957,000$970.23M$-162,389,000$-54,510,000$-40,218,000$-45,453,000$5.82M$-118,164,000
    Interest Income$-48,481,000$-49,030,000$-55,188,000$-32,592,000$-30,358,000$-34,092,000$58.84M$-41,609,000$-43,490,000$-40,834,000$-44,274,000$-28,160,000
    Interest Expense$51.43M$47.42M$67.73M$0$36.09M$40.40M$0$0$0$0$137.56M$0
    Income Before Tax$97.55M$-2,462,000$-139,083,000$-23,074,000$-71,052,000$929.83M$-94,699,000$-97,991,000$-85,733,000$-84,696,000$-157,051,000$-166,590,000
    Income Tax Expense$14.05M$347,000$-4,118,000$-38,970,000$-6,203,000$63.27M$-28,813,000$8.66M$13.45M$6.88M$-1,259,000$-33,620,000
    Net Income$83.50M$-2,809,000$-134,965,000$15.90M$-64,849,000$866.56M$-65,886,000$-106,654,000$-99,179,000$-91,576,000$-155,792,000$-132,970,000
    EBITDA$158.13M$58.17M$-75,730,000$14.83M$-37,365,000$969.13M$-149,050,000$-52,550,000$-38,226,000$8.13M$103.67M$-75,803,000
    EBIT$146.03M$46.57M$-83,895,000$9.52M$-40,694,000$963.92M$-153,539,000$-56,382,000$-42,243,000$-43,862,000$24.78M$-138,430,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about PTCT

    News

    PTC Therapeutics (NASDAQ:PTCT) Now Covered by Analysts at Truist Financial

    Truist Financial has initiated coverage on PTC Therapeutics (NASDAQ:PTCT) with a "hold" rating and a $62 price target...

    MarketBeat•10/16/26•Somewhat-Bullish

    UBS Adjusts Price Target on PTC Therapeutics to $90 From $80, Maintains Buy Rating

    UBS has increased its price target for PTC Therapeutics (PTCT) from $80 to $90, while reiterating a Buy rating on the stock. This adjustment suggests a positive outlook on the company's future performance.

    Moomoo•10/15/26•Bullish

    UBS lifts PTC Therapeutics stock target to USD 90.00

    UBS has increased its price target for PTC Therapeutics (PTCT) to USD 90.00 from USD 80.00, maintaining a Buy rating. This adjustment follows PTC Therapeutics' strong second-quarter 2026 revenue of USD 360.52 million...

    ad-hoc-news.de•10/15/26•Bullish

    UBS Adjusts Price Target on PTC Therapeutics to $90 From $80, Maintains Buy Rating

    UBS has increased its price target for PTC Therapeutics (PTCT) to $90 from $80, while maintaining a Buy rating on the stock. The company currently has an average rating of overweight and a mean price target of $100.33...

    Yahoo Finance•10/15/26•Bullish

    PTC Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, Oct. 29, 2026

    PTC Therapeutics, Inc. (PTCT) announced it will host a webcast conference call on Thursday, October 29, 2026, at 4:30 p.m. ET to discuss its third quarter 2026 financial results and provide a business update. Interested...

    TradingView•10/15/26•Neutral

    PTCT Valuation and Fair Value

    P/E
    -84.7x
    Forward P/E
    22.7x
    EV/EBITDA
    29.6x
    P/FCF
    -127.5x
    PEG
    0.8x
    P/B
    -30.6x
    See GNG's fair value

    PTCT Profitability: Margins, ROIC and FCF

    Gross margin
    97.7%
    Operating margin
    41.3%
    Net margin
    -3.8%
    ROIC
    18.1%
    ROE
    -7740.0%
    FCF margin
    -3.9%
    FCF yield
    -0.8%

    PTCT Competitors

    CompanyTicker
    Sotera Health CoSHC
    Travere Therapeutics IncTVTX
    Oruka Therapeutics, Inc.ORKA
    Terns Pharmaceuticals IncTERN
    Erasca IncERAS
    Cogent Biosciences IncCOGT
    Waystar Holding Corp. Common StockWAY
    Grifols SA ADRGRFS

    Sector: Healthcare

    PTCT Analyst Ratings

    Consensus
    Buy
    Analysts
    14
    Strong Buy
    4
    Buy
    8
    Hold
    1
    Sell
    1
    Strong Sell
    0

    PTCT Bull Case vs Bear Case

    Bull case

    • PTCT earns an 18.1% return on invested capital.
    • PTCT beat EPS estimates in 87.5% of its last 8 reported quarters.
    • PTCT grew quarterly revenue 101.5% year over year.

    Bear case

    • PTCT has a -3.8% net profit margin.

    PTCT Earnings: Beat Rate and Next Report

    Beat rate
    7 of 8 quarters (87.5%)
    Average surprise
    265.5%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $0.30
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 0 down

    Frequently Asked Questions About PTCT

    Does PTCT pay dividends?

    PTC Therapeutics Inc (PTCT) does not currently pay a regular dividend.

    What is PTCT's market cap?

    PTC Therapeutics Inc (PTCT) has a market capitalization of $4.98B with a current stock price of $60.99.

    Related stocks

    Sector: Healthcare

    All stocks starting with P

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In